Anika Therapeutics (NASDAQ:ANIK – Get Free Report) is projected to release its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of $0.42 per share and revenue of $29.44 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.39. Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%. The company had revenue of $32.61 million during the quarter, compared to analyst estimates of $29.21 million. On average, analysts expect Anika Therapeutics to post $0.14 EPS for the current fiscal year and $0.29 EPS for the next fiscal year.
Anika Therapeutics Trading Up 1.1%
Anika Therapeutics stock opened at $21.79 on Friday. The stock’s 50 day simple moving average is $20.67 and its two-hundred day simple moving average is $15.97. Anika Therapeutics has a 12 month low of $9.01 and a 12 month high of $22.88. The firm has a market cap of $291.55 million, a PE ratio of 1,077.50, a P/E/G ratio of 15.39 and a beta of 0.21.
Analysts Set New Price Targets
View Our Latest Report on ANIK
Anika Therapeutics Company Profile
Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.
Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.
See Also
- Five stocks we like better than Anika Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
